Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041678 · ClinicalTrials.gov registry record · Phase 3
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
A Phase 3 study of Alzheimer Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 6
- Study locations
NCT00041678 is a Phase 3 study of Alzheimer Disease that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The trial reports 6 study locations across 5 states.
The verdict
NCT00041678, a Phase 3 study of Alzheimer Disease, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6
- Study locations
Study Summary
The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
Conditions Studied
Interventions
- DRUG aripiprazole
Study Locations (6)
Vermont
- Local Institution - Bennington
- Local Institution - Burlington
California
- Local Institution - Rosemead
Florida
- Local Institution - Miami
Tennessee
- Local Institution - Nashville
Wisconsin
- Local Institution - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-01 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00041678
The ClinicalTrials.gov registry entry for NCT00041678 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which aripiprazole is the first listed.
NCT00041678 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Vermont, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00041678 about?
NCT00041678 is a clinical study titled "Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type". The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
What is the current status of trial NCT00041678?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-01. Estimated completion is 2003-03.
What conditions does trial NCT00041678 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT00041678?
The interventions under investigation include: aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00041678?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00041678 being conducted?
This trial has 6 study locations across California, Florida, Tennessee, Vermont, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Biomarker Exploration in Aging, Cognition and Neurodegeneration
RECRUITING · Phase 3
-
Epidemiology and Biomarker Study in Alzheimer's Disease
RECRUITING · Phase 3
-
[18F]PI-2620 Phase 3 Histopathological Study
RECRUITING · Phase 3
-
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
RECRUITING · Phase 3
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.